About Us
Overview
Our Business
Board of Directors
Executive Leadership Team
Our Stories
Biocon Biologics Malaysia
Scientific Publications
Awards & Recognition
Our Legacy
Business
Global Biosimilars Portfolio
Oncology
Immunology
Diabetology
Ophthalmology
Bone Health & Others
Our Products
Global
India
Partners
Global Footprint
Capabilities
Research & Development
Quality & Compliance
Global Scale Manufacturing
Commitment
Investors
News
Press Releases
Company Statements
Our Stories
Media Contacts
Careers
Working With Us
Now Hiring
Contact Us
University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw
Tue, 29-Mar-2022
Posted by: Biocon Biologics
No Comments
Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)
Wed, 23-Mar-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics to Acquire Viatris’ Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Mon, 28-Feb-2022
Posted by: Biocon Biologics
No Comments
Biocon Q3FY22 Revenue at Rs 2,223 Cr, Up 18%; EBITDA at Rs 537 Cr, Up 25%; Biosimilars Up 28% at Rs 981 Cr; Research Services Up 10% at Rs 641 Cr; Generics Up 7% at Rs 607 Cr
Thu, 20-Jan-2022
Posted by: Biocon Biologics
No Comments
The USFDA issues a complete response letter for the Biologics License Application (BLA) for insulin Aspart
Fri, 07-Jan-2022
Posted by: Biocon Biologics
No Comments
Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus® Device Patents
Thu, 30-Dec-2021
Posted by: Biocon Biologics
No Comments
Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGI Approval
Thu, 23-Dec-2021
Posted by: Biocon Biologics
No Comments
Biocon Enters Prestigious Dow Jones Sustainability Emerging Markets Index
Wed, 01-Dec-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club
Fri, 19-Nov-2021
Posted by: Biocon Biologics
No Comments
Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection
Tue, 16-Nov-2021
Posted by: Biocon Biologics
No Comments
1
2
3
4
5
…
19